BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25224279)

  • 1. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
    Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
    Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
    Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
    Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
    Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Boven E; Stegmann AP; Hermsen M; Vermorken JB; Pinedo HM; Peters GJ
    Cancer Res; 1994 Aug; 54(15):4138-43. PubMed ID: 8033147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
    Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
    Sigmond J; Kroep JR; Loves W; Codacci-Pisanelli G; Peters GJ
    Cancer Lett; 2004 Sep; 213(2):173-9. PubMed ID: 15327832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
    Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
    Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
    Nakano T; Saiki Y; Kudo C; Hirayama A; Mizuguchi Y; Fujiwara S; Soga T; Sunamura M; Matsumura N; Motoi F; Unno M; Horii A
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1084-1089. PubMed ID: 26196746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased drug resistance of bladder cancer using phytochemicals treatment.
    Cho CJ; Yu CP; Wu CL; Ho JY; Yang CW; Yu DS
    Kaohsiung J Med Sci; 2021 Feb; 37(2):128-135. PubMed ID: 33280258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
    Blackstock AW; Lightfoot H; Case LD; Tepper JE; Mukherji SK; Mitchell BS; Swarts SG; Hess SM
    Clin Cancer Res; 2001 Oct; 7(10):3263-8. PubMed ID: 11595723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
    Di Cresce C; Figueredo R; Rytelewski M; Maleki Vareki S; Way C; Ferguson PJ; Vincent MD; Koropatnick J
    Oncotarget; 2015 Sep; 6(26):22397-409. PubMed ID: 26087398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.